<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489164</url>
  </required_header>
  <id_info>
    <org_study_id>P02-6316, P01-6311</org_study_id>
    <nct_id>NCT00489164</nct_id>
  </id_info>
  <brief_title>Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions</brief_title>
  <acronym>DECODE</acronym>
  <official_title>A Randomized Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions (DECODE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess in-stent late lumen loss in diabetic patients&#xD;
      with de novo native coronary lesions using the sirolimus-eluting Bx VELOCITYÃ¤ stent as&#xD;
      compared to the Bx VELOCITY balloon-expandable stent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss as measured by QCA at six months post-procedure. In-stent measurement is defined as the measurement within the stented segment.</measure>
    <time_frame>6 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days, 6 months and 1 year post-procedure</measure>
    <time_frame>at 30 days, 6 months and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) and target vessel revascularization (TVR) at 30 days, 6 months and 1 year post-procedure</measure>
    <time_frame>at 30 days, 6 months and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 30 days, 6 months and 1 year post-procedure</measure>
    <time_frame>at 30 days, 6 months and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success defined as achievement of a final residual diameter stenosis of &lt;50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success defined as the attainment of &lt;50% residual stenosis (by QCA) using any percutaneous method</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success defined as achievement of a final diameter stenosis of &lt;50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent mean percent diameter stenosis (%DS), Binary restenosis and late lumen loss as measured by quantitative coronary angiography at post-procedure and at 6-months</measure>
    <time_frame>at post-procedure and at 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-lesion mean percent diameter stenosis (%DS), mean lumen diameter (MLD), binary restenosis and late lumen loss as measured by quantitative coronary angiography at post-procedure and at 6-months</measure>
    <time_frame>at post-procedure and at 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic control as measured by HbA1C at 6 months and 1 year follow-up</measure>
    <time_frame>at 6 months and 1 year follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">83</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-Eluting BX Velocity Balloon-Expandable Stent</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be 18 years of age;&#xD;
&#xD;
          2. Patients must be previously diagnosed with Type I or Type II diabetes with documented&#xD;
             treatment with insulin or oral hypoglycemics by medical history. (Undocumented or&#xD;
             newly diagnosed diabetics must have fasting plasma glucose of &gt;/= 126 mg/dl or a 2h&#xD;
             post-load value in the OGTT &gt;/=200 mg/dl, confirmed on alternate days);&#xD;
&#xD;
          3. Female of childbearing potential must have a negative pregnancy test and must plan to&#xD;
             be on accepted method of contraception for 6 months after time of enrollment;&#xD;
&#xD;
          4. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society&#xD;
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald&#xD;
             Classification B&amp;C, I-II-III) OR patients with documented silent ischemia;&#xD;
&#xD;
          5. Treatment of lesions in native coronary arteries requiring a maximum of three stents&#xD;
             per patient. Multi-vessel treatment is permissible. Additional stents may be used for&#xD;
             procedural complications such as dissections. Patients with additional lesions can be&#xD;
             included only if the other lesions are not considered clinically significant and do&#xD;
             not require treatment;&#xD;
&#xD;
          6. Target lesion is &gt;/=2.25 and &lt;/=3.0 in diameter (visual estimate);&#xD;
&#xD;
          7. Individual lesions are &gt;/=10 mm to &lt;/= 32 mm in length located in a native coronary&#xD;
             artery;&#xD;
&#xD;
          8. Target lesions are de novo lesions in native coronary vessels;&#xD;
&#xD;
          9. Acceptable candidate for coronary artery bypass surgery (CABG);&#xD;
&#xD;
         10. Target lesion stenosis is &gt;50% and &lt;100% (TIMI I) (visual estimate);&#xD;
&#xD;
         11. Patient is willing to comply with the specified follow-up evaluation;&#xD;
&#xD;
         12. Patient must provide written informed consent prior to the procedure using a form that&#xD;
             is approved by the local Institutional Review Board.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented&#xD;
             total CK&gt;2 times normal within the preceding 24 hours and the CK and CK-MB enzymes&#xD;
             remains above normal at the time of treatment;&#xD;
&#xD;
          2. Unprotected left main coronary disease with 50% stenosis;&#xD;
&#xD;
          3. Significant (&gt;/=50%) stenoses proximal or distal to the target lesion that might&#xD;
             require revascularization or impede runoff;&#xD;
&#xD;
          4. Patients admitted for treatment of diabetic ketoacidosis &gt;/= 2 times in the past six&#xD;
             months (Brittle Diabetics);&#xD;
&#xD;
          5. Intervention of another lesion has occurred within six months prior to index&#xD;
             procedure;&#xD;
&#xD;
          6. Have an ostial target lesion;&#xD;
&#xD;
          7. Target lesion is in a saphenous venous graft.&#xD;
&#xD;
          8. Target lesion is due to in-stent restenosis.&#xD;
&#xD;
          9. Angiographic evidence of thrombus within target lesion;&#xD;
&#xD;
         10. Calcified lesions which cannot be successfully predilated;&#xD;
&#xD;
         11. Ejection fraction &lt;/=30%;&#xD;
&#xD;
         12. Totally occluded vessel (TIMI 0 level);&#xD;
&#xD;
         13. Impaired renal function (creatinine &gt; 2.0 mg/dL);&#xD;
&#xD;
         14. Target lesion has excessive tortuosity unsuitable for stent delivery and deployment;&#xD;
&#xD;
         15. Pretreatment with devices other than balloon angioplasty (direct stenting is not&#xD;
             allowed);&#xD;
&#xD;
         16. Target lesion involves bifurcation including a side branch &gt;/=2.5mm in diameter&#xD;
             (either stenosis of both main vessel and major branch or stenosis of just major&#xD;
             branch) that would require side branch stenting which is likely to occur if side&#xD;
             branch is diseased and intended to be stented;&#xD;
&#xD;
         17. Previous brachytherapy of target vessel;&#xD;
&#xD;
         18. Recipient of heart transplant;&#xD;
&#xD;
         19. Patient with a life expectancy less than 12 months;&#xD;
&#xD;
         20. Known allergies to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid),&#xD;
             heparin, stainless steel, contrast agent or sirolimus, that cannot be medically&#xD;
             managed;&#xD;
&#xD;
         21. Any significant medical condition which in the investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study;&#xD;
&#xD;
         22. Currently participating in an investigational drug or another device study;&#xD;
&#xD;
         23. Treatment with Metformin (glucophage) within 48 hours of angiogram.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Buchbinder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foundation for Cardiovascular Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Batra Hospital &amp; Research Centre</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital &amp; Research Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escorts Heart Institute &amp; Research Centre</name>
      <address>
        <city>New Delhi</city>
        <zip>110 025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Center</name>
      <address>
        <city>Singapore</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M; DECODE Investigators. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter Cardiovasc Interv. 2008 Nov 1;72(5):591-600. doi: 10.1002/ccd.21719.</citation>
    <PMID>18949772</PMID>
  </results_reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>November 10, 2008</last_update_submitted>
  <last_update_submitted_qc>November 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2008</last_update_posted>
  <keyword>DIABETIC PATIENTS WITH NATIVE CORONARY ARTERY LESIONS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

